Posts Tagged: AuRA (Amplified Redox Assay)

Xagenic announces $6 million GAAP partnership for Hepatitis C testing; appoints president and CEO

Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, announced October 15, 2014 that its project in partnership with the University of Toronto was successful in securing funding from Genome Canada under the Genomic Applications Partnership Program (GAPP). The funding, announced by the Honourable Ed Holder, Minister of State (Science and Technology) and Dr. Pierre Meulien, president and CEO of Genome Canada, is part of 12 selected projects under Genome Canada’s Genomic Applications ... Read more

Frost & Sullivan awards Xagenic award for new product innovation leadership

Market research company lauds start-up for developing a breakthrough workflow while dramatically improving point-of-care diagnosis (MOUNTAIN VIEW, Calif) May 20, 2014 — Based on its recent analysis of the point-of-care diagnostics market, Frost & Sullivan recognizes Xagenic Inc. with the 2014 North America Frost & Sullivan Award for New Product Innovation Leadership. Xagenic’s revolutionary product, the Xagenic X1™ system, is a point-of-care platform with intuitive features to provide lab-free molecular diagnostic testing. It is unique as a low-cost, simple, rapid sample-to-answer desktop instrument, ... Read more

MaRS Innovation focus of Yonge Street Media article on growing technology sectors

President and CEO Dr. Raphael Hofstein speaks on healthcare innovation in Toronto In an October 30 article, Yonge Street Media's Andrew Seale spoke with MI’s president and CEO Raphael Hofstein on the booming healthcare innovation coming from Toronto since 2005. Seale's article is the first of a two-part series on technological innovation. In the article, Hofstein credits the city’s intellectual infrastructure and access to healthcare resources for allowing innovation to flourish. Three of MI’s start-up companies are also mentioned in the article. Here’s an excerpt (links and ... Read more

MaRS Innovation’s Lead Start-Up Completes $20 Million Series B

Xagenic’s financing round to test platform and first diagnostic assay, continue product development and begin FDA submission Toronto, ON (December 2, 2013) — MaRS Innovation’s first start-up company, Xagenic Inc., is developing the first lab-free molecular diagnostic platform with a 20-minute time-to-result based on University of Toronto research by Professors Shana Kelley and Edward Sargent. Today, Xagenic announced it has successfully closed a Series B financing round totaling $20 million. New investor Domain Associates, LLC, led the round, joined by existing investors who ... Read more